Core Viewpoint The Guangdong Jiaying Pharmaceutical Co., Ltd. is preparing for its 2024 Annual General Meeting, focusing on various proposals including financial reports, profit distribution plans, and corporate governance matters. Group 1: Meeting Details - The meeting is scheduled for May 16, 2025, at 14:30 in Meizhou, Guangdong Province [5] - Attendees will include shareholders, company directors, supervisors, senior management, and invited guests [5] Group 2: Proposals for Review - Proposal 1: Review of the 2024 Annual Report and its summary [6] - Proposal 2: Review of the 2024 Financial Settlement Report, audited by Zhonghua Accounting Firm [7] - Proposal 3: Profit distribution plan for 2024, which proposes no cash dividends or stock bonuses [9][11] - Proposal 4: Review of the 2024 Board of Directors' Work Report, highlighting operational achievements and challenges [14] - Proposal 5: Review of the 2024 Supervisory Board's Work Report, detailing compliance and oversight activities [32] - Proposal 6: Confirmation of 2024 director remuneration and proposal for 2025 remuneration [36] - Proposal 7: Request for a comprehensive credit limit of up to RMB 200 million from banks for operational needs [37] - Proposal 8: Review of daily related party transactions for 2024 and projections for 2025 [40] Group 3: Financial Performance and Strategy - The company reported a net profit of RMB 16,346,842.23 for 2024, with no cash dividends proposed due to financial constraints and strategic investments [9][11] - The company aims to enhance its product portfolio and reduce reliance on a single product line, particularly in response to market fluctuations affecting its main products [11][12] - The company plans to invest in research and development to diversify its offerings and improve market competitiveness [29][30] Group 4: Corporate Governance and Compliance - The company has established a robust internal control system to ensure compliance with laws and regulations, maintaining transparency and protecting shareholder interests [33][35] - The Supervisory Board has actively monitored the company's operations, ensuring adherence to legal and regulatory standards [32][34]

Core Viewpoint - The company, Jiajing Pharmaceutical, has shown significant improvement in its financial performance, achieving both revenue and profit growth in the first quarter of 2025, driven by cost reductions and increased sales volume [2][3]. Financial Performance - In Q1 2025, Jiajing Pharmaceutical reported revenue of 122 million yuan, a year-on-year increase of 28.83%, effectively halting six consecutive quarters of revenue decline [3] - Net profit surged by 197.23% to 15.75 million yuan, marking two consecutive quarters of profitability [3] - The sales gross margin reached 66.81%, the highest since 2022, attributed to revenue growth and improved product gross margins [3] Cost Structure and Raw Material Prices - The improvement in gross margin is primarily due to a decline in raw material prices, with the Chinese herbal medicine price index dropping by 10% year-on-year in Q1 2025 [4] - Key raw materials for Jiajing Pharmaceutical's core product, Shuangliao Houfeng San, have seen price reductions exceeding 30% since their peak in 2024 [7] - Raw material costs account for over 60% of the company's total costs, and the recent price declines have alleviated cost pressures significantly [7] Operational Efficiency - The company has enhanced its production efficiency through automation and improved production processes, which have lowered production costs [8] - Jiajing Pharmaceutical has implemented refined operations to ensure product profitability, focusing on quality management and efficient production planning [8] Product Portfolio and Market Strategy - Jiajing Pharmaceutical is focusing on two main product categories: throat and orthopedic products, with a strategy to develop best-selling products and accelerate new product launches [10][12] - The company has a diverse product lineup, including 70 approved drug varieties, with core products like Shuangliao Houfeng San and Jiekou Qili series accounting for over 66% of revenue [10] Strategic Partnerships and Market Expansion - The acquisition of a 7% stake by Yangtianhe has improved Jiajing Pharmaceutical's market coverage and sales channels, leveraging Yangtianhe's extensive retail network [15] - The collaboration aims to create a dual-driven model of "pharmaceutical commerce + pharmaceutical industry," enhancing resource sharing and market reach [15] - Jiajing Pharmaceutical plans to strengthen partnerships with major retail chains and expand its online sales channels to increase market share [17]